NRG GY018: Pembrolizumab in Advanced Endometrial Cancer
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Study Summaries
MITO-7: Weekly chemotherapy in ovarian cancer
Weekly chemotherapy vs. q3 weekly chemotherapy in advanced ovarian cancer
BEATcc: Atezolizumab added to Cis/Taxol/Bev in recurrent/metastatic cervical cancer
Atezolizumab plus bevacizumab and chemotherapy for
metastatic, persistent, or recurrent cervical cancer (BEATcc)
GOG 281: Trametinib in recurrent low-grade serous ovarian cancer
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer.
MIRASOL: Mirvetuximab in Platinum Resistant Cancer
Mirvetuximab Soravtansine (MIRV) in platinum resistant ovarian cancer
EORTC-55994 and Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
EORTC and the trial from TATA memorial. Is neoadjuvant chemotherapy and surgery an alternative to chemoradiation in locally advanced cervical cancer?
DUO-E Trial
Does adding durvalumab (a PD-L1 inhibitor) and olaparib (a PARP inhibitor) to standard chemotherapy improve outcomes in advanced or recurrent endometrial cancer?
OUTBACK Trial: Chemotherapy after Chemoradiation
OUTBACK trial